Search Results

You are looking at 1 - 10 of 290 items for :

  • "gemcitabine" x
  • Refine by Access: All x
Clear All
Full access

Andrew H. Ko and Margaret A. Tempero

– 755 . 5 Burris HA 3rd Moore MJ Andersen J . Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial . J Clin Oncol 1997 ; 15 : 2403 – 2413

Full access

Nikolaos A. Trikalinos, Amy Zhou, Maria B. Majella Doyle, Kathryn J. Fowler, Ashley Morton, Neeta Vachharajani, Manik Amin, Jesse W. Keller, William C. Chapman, Elizabeth M. Brunt, and Benjamin R. Tan

experienced recurrence at an average interval of 9.6 (± 8.7) months. Most patients who received chemotherapy were ultimately treated with a gemcitabine-based regimen (57/68); 16 (23.5%) received gemcitabine alone or in combination with a fluoropyrimidine (5

Full access

Margaret A. Tempero

essentially be summarized as a half dozen clinical trials evaluating gemcitabine and 5-fluorouracil (FU), with and without radiation. Outcomes from these trials were largely similar, with median OS hovering around 22 months and 25% to 30% of patients dying of

Full access

Margaret A. Tempero, J. Pablo Arnoletti, Stephen Behrman, Edgar Ben-Josef, Al B. Benson III, Jordan D. Berlin, John L. Cameron, Ephraim S. Casper, Steven J. Cohen, Michelle Duff, Joshua D.I. Ellenhorn, William G. Hawkins, John P. Hoffman, Boris W. Kuvshinoff II, Mokenge P. Malafa, Peter Muscarella II, Eric K. Nakakura, Aaron R. Sasson, Sarah P. Thayer, Douglas S. Tyler, Robert S. Warren, Samuel Whiting, Christopher Willett, and Robert A. Wolff

performed after administration of each treatment modality, when systemic gemcitabine is followed by chemoradiation in the adjuvant setting. In addition, this restaging is also recommended after administration of neoadjuvant therapy and before surgical

Full access

Cintia Yoko Morioka, Marcel Cerqueira Cesar Machado, Jose Pinhata Otoch, Luma Princess Schneider, Edgard Mesquita Rodrigues Lima, Marcelo Engracia Garcia, Joelmir Silva, Alessandro Costa, Victor Herrera, Paulo Aguiar, Elenir Herrera, Talita Aguiar, Maycon Kublik, Amelia Silva, Kennedy Silva, Eduardo Morioka, and Ching Cheng Huang

were used for the experiments. 5-Fluorouracil (5FU), Gemcitabine (GEM) and green tea extract (GTE) were used. MTT assay and MTT agarose assay were performed. In vitro chemoinvasion assay was done. RESULTS: The inhibitory concentration (IC50) of 5-FU

Full access

Angela M. Davies, Philip C. Mack, Primo N. Lara Jr., Derick H. Lau, Kathleen Danenberg, Paul H. Gumerlock, and David R. Gandara

Lord RV Brabender J Gandara D . Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer . Clin Cancer Res 2002 ; 8 : 2286 – 2291 . 11 Rosell-Costa R Danenberg K

Full access

Heike Reinhardt, Rainer Trittler, Alison G. Eggleton, Stefan Wöhrl, Thomas Epting, Marion Buck, Sabine Kaiser, Daniel Jonas, Justus Duyster, Manfred Jung, Martin J. Hug, and Monika Engelhardt

. 8 The number of production cycles required per year was determined from published stability data by dividing 52 by the stability in weeks of the respective drug. 10 , 11 Using gemcitabine as an example, assuming a stability of 12 weeks, 11 5

Full access

Keli Turner, Sheelu Varghese, and H. Richard Alexander

overall response rates (including no complete responders in both groups), suggesting either regimen may be used beyond first-line chemotherapy. Table 1 Pemetrexed Alone Versus With Cisplatin or Gemcitabine The results of a second phase II

Full access

Esther N. Pijnappel, Willemieke P.M. Dijksterhuis, Lydia G. van der Geest, Judith de Vos-Geelen, Jan Willem B. de Groot, Marjolein Y.V. Homs, Geert-jan Creemers, Nadia Haj Mohammad, Marc G. Besselink, Hanneke W.M. van Laarhoven, Johanna W. Wilmink, and for the Dutch Pancreatic Cancer Group

, chemotherapy is the cornerstone of treatment. 3 – 5 However, international consensus on the most optimal first- and second-line palliative systemic treatment regimen is lacking. Since 1997, single-agent gemcitabine has been the standard first-line palliative

Full access

-37. Factors Potentially Associated With Gemcitabine-Based, Chemotherapy-Induced Thrombocytopenia in Chinese Patients With Non–Small Cell Lung Cancer Zeng Wang; Ling Ya Chen; Wen Xiu Xin; Bin Cheng; and Ping Huang From Zhejiang Cancer Hospital, People